$39.65
-6.06-13.26%
Last update: Nov 6, 4:00 PM
Rigel Pharmaceuticals Inc
RIGLNASDAQ
Rigel Pharmaceuticals (RIGL) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Rigel Pharmaceuticals (RIGL) last issued guidance on November 5, 2026 for fiscal year 2026. The company guided revenue in the range of $290M - $295M for the period.
Compared to prior guidance, Rigel Pharmaceuticals maintained its revenue forecast from a prior range of $285M - $295M.
Rigel Pharmaceuticals has issued 16 guidance updates between January 9, 2023 and November 5, 2026. During this period, the company raised its outlook 7 times and lowered it 3 times, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.94 | $0.17 | $0.85 | $1.25 |
| Actual | $0.65 | $0.88 | $0.44 | $1.12 |
| Surprise | -30.9% | +417.6% | -48.2% | -10.4% |
| Revenue | ||||
| Estimate | $79.7M | $58.6M | $62.0M | $69.1M |
| Actual | $80.9M | $78.7M | $58.8M | $69.8M |
| Surprise | +1.45% | +34.2% | -5.11% | +0.95% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $1.02 | $0.55 | $0.80 | $0.85 |
| Revenue | ||||
| Consensus | $87.1M | $76.3M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $0.65 | $0.94 | -30.9 % |
| Q2 | Aug 4, 2026 | $0.88 | $0.17 | 417.6 % |
| Q1 | May 5, 2026 | $0.44 | $0.85 | -48.2 % |
| Q4 | Mar 3, 2026 | $1.12 | $1.25 | -10.4 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $80.89M | $79.73M | 1.45 % |
| Q2 | Aug 4, 2026 | $78.70M | $58.63M | 34.2 % |
| Q1 | May 5, 2026 | $58.80M | $61.97M | -5.11 % |
| Q4 | Mar 3, 2026 | $69.80M | $69.14M | 0.95 % |
